Publications

IFN-γ-independent immune markers of Mycobacterium tuberculosis exposure

Lu LL, Smith MT, Yu KKQ, Luedemann C, Suscovich TJ, Grace PS, Cain A, Yu WH, McKitrick TR, Lauffenburger D, Cummings RD, Mayanja-Kizza H, Hawn TR, Boom WH, Stein CM, Fortune SM, Seshadri C, Alter G, 2019 06 Nat. Med. 6 25 977-987

Beyond binding: antibody effector functions in infectious diseases.

Lu LL, Suscovich TJ, Fortune SM, Alter G, 2018 Jan Nat. Rev. Immunol. 1 18 46-61

A Functional Role for Antibodies in Tuberculosis.

Lu LL, Chung AW, Rosebrock TR, Ghebremichael M, Yu WH, Grace PS, Schoen MK, Tafesse F, Martin C, Leung V, Mahan AE, Sips M, Kumar MP, Tedesco J, Robinson H, Tkachenko E, Draghi M, Freedberg KJ, Streeck H, Suscovich TJ, Lauffenburger DA, Restrepo BI, Day C, Fortune SM, Alter G, 2016 Oct Cell 2 167 433-443.e14

BNT162b2-induced neutralizing and non-neutralizing antibody functions against SARS-CoV-2 diminish with age.

Bates TA, Lu P, Kang YJ, Schoen D, Thornton M, McBride SK, Park C, Kim D, Messer WB, Curlin ME, Tafesse FG, Lu LL, 2022 Oct Cell Rep 4 41 111544

Engineering the supernatural: monoclonal antibodies for challenging infectious diseases.

Grace PS, Gunn BM, Lu LL, 2022 Oct Curr Opin Biotechnol 78 102818

Leveraging Antibody, B Cell and Fc Receptor Interactions to Understand Heterogeneous Immune Responses in Tuberculosis.

Carpenter SM, Lu LL, 2022 Front Immunol 13 830482

Antibody Subclass and Glycosylation Shift Following Effective TB Treatment.

Grace PS, Dolatshahi S, Lu LL, Cain A, Palmieri F, Petrone L, Fortune SM, Ottenhoff THM, Lauffenburger DA, Goletti D, Joosten SA, Alter G, 2021 Front Immunol 12 679973

Antibody Fc Glycosylation Discriminates Between Latent and Active Tuberculosis.

Lu LL, Das J, Grace PS, Fortune SM, Restrepo BI, Alter G, 2020 Feb J. Infect. Dis.

Unique repertoire of anti-carbohydrate antibodies in individual human serum.

Luetscher RND, McKitrick TR, Gao C, Mehta AY, McQuillan AM, Kardish R, Boligan KF, Song X, Lu L, Heimburg-Molinaro J, von Gunten S, Alter G, Cummings RD, 2020 09 Sci Rep 1 10 15436

Moving toward Tuberculosis Elimination. Critical Issues for Research in Diagnostics and Therapeutics for Tuberculosis Infection.

Keshavjee S, Amanullah F, Cattamanchi A, Chaisson R, Dobos KM, Fox GJ, Gendelman HE, Gordon R, Hesseling A, Le Van H, Kampmann B, Kana B, Khuller G, Lewinsohn DM, Lewinsohn DA, Lin PL, Lu LL, Maartens G, Owen A, Protopopova M, Rengarajan J, Rubin E, Salgame P, Schurr E, Seddon JA, Swindells S, Tobin DM, Udwadia Z, Walzl G, Srinivasan S, Rustomjee R, Nahid P, 2019 Mar Am. J. Respir. Crit. Care Med. 5 199 564-571

Publisher Correction: IFN-γ-independent immune markers of Mycobacterium tuberculosis exposure

An Inflammatory Story: Antibodies in Tuberculosis Comorbidities.

McLean MR, Lu LL, Kent SJ, Chung AW, 2019 Front Immunol 10 2846

Introduction: Physician-Scientists in the Evolving Landscape of Biomedical Research.

Lu LL, Kwon DS, Barczak AK, 2018 Aug J. Infect. Dis. suppl_1 218 S1-S2

Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine.

Hansen SG, Zak DE, Xu G, Ford JC, Marshall EE, Malouli D, Gilbride RM, Hughes CM, Ventura AB, Ainslie E, Randall KT, Selseth AN, Rundstrom P, Herlache L, Lewis MS, Park H, Planer SL, Turner JM, Fischer M, Armstrong C, Zweig RC, Valvo J, Braun JM, Shankar S, Lu L, Sylwester AW, Legasse AW, Messerle M, Jarvis MA, Amon LM, Aderem A, Alter G, Laddy DJ, Stone M, Bonavia A, Evans TG, Axthelm MK, Früh K, Edlefsen PT, Picker LJ, 2018 02 Nat. Med. 2 24 130-143

The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial.

Coler RN, Day TA, Ellis R, Piazza FM, Beckmann AM, Vergara J, Rolf T, Lu L, Alter G, Hokey D, Jayashankar L, Walker R, Snowden MA, Evans T, Ginsberg A, Reed SG, 2018 NPJ Vaccines 3 34

Antibodies to Mycobacterium tuberculosis.

Casadevall A, 2017 01 N Engl J Med 3 376 283-285

To Be or Not Be a (Functional) Antibody Against TB.

Casadevall A, 2016 Oct Cell 2 167 306-307

Antibodies: Marking disease states in tuberculosis.

Kugelberg E, 2016 10 Nat Rev Immunol 11 16 660

Select paramyxoviral V proteins inhibit IRF3 activation by acting as alternative substrates for inhibitor of kappaB kinase epsilon (IKKe)/TBK1.

Lu LL, Puri M, Horvath CM, Sen GC, 2008 May J. Biol. Chem. 21 283 14269-76

Mutations in SID2, a novel gene in Saccharomyces cerevisiae, cause synthetic lethality with sic1 deletion and may cause a defect during S phase.

Jacobson MD, Muñoz CX, Knox KS, Williams BE, Lu LL, Cross FR, Vallen EA, 2001 Sep Genetics 1 159 17-33